# US 12,180,267 B2 · Methods and composition for neutralization of influenza

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 12,180,267 B2
- Document ID: US12180267B2
- Status: Granted
- Kind: B2
- Application number: 18/335,874
- Filed: 2023-06-15
- Published: 2024-04-11
- Granted: 2024-12-31
- Earliest claimed: 2018-03-02
- Assignees: The University of Chicago
- Applicants: The University of Chicago
- Inventors: Patrick Wilson; Yaoqing Chen; Haley L. Dugan
- Web page: https://patentgrep.com/patent/US12180267B2

## CPC

- C07K 16/108: Orthomyxoviridae (F), e.g. influenza virus
- A61K 39/12: Viral antigens
- A61K 39/42: viral
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 31/16: for influenza or rhinoviruses
- A61K 2039/505: {comprising antibodies}
- A61K 2039/5252: {inactivated (killed)}
- A61K 2039/543: {intranasal}
- A61K 2039/545: {characterised by the dose, timing or administration schedule}
- A61K 2039/575: {humoral response}
- C07K 2317/21: from primates, e.g. man
- C07K 2317/33: Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
- C07K 2317/34: Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
- C07K 2317/565: Complementarity determining region [CDR]
- C07K 2317/76: Antagonist effect on antigen, e.g. neutralization or inhibition of binding
- C07K 2317/92: Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
- C12N 2760/16134: Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

Provided herein are anti-neuraminidase agents useful for neutralization of influenza virus infection, and methods of use and manufacture thereof. In particular, compositions comprising anti-neuraminidase agents (e.g., antibodies) that are cross-reactive with multiple influenza strains are provided, as well as methods of treatment and prevention of influenza infection therewith.

## Claims

### Claim 1

An antibody or antibody fragment comprising a heavy chain variable region comprising a CDR1 of SEQ ID NO: 20, a CDR2 of SEQ ID NO: 22 and CDR3 of SEQ ID NO: 24, and a light chain variable region comprising a CDR1 of SEQ ID NO: 28, a CDR2 of SEQ ID NO: 30 and CDR3 of SEQ ID NO: 32 wherein the antibody or antibody fragment is capable of binding to influenza neuraminidase (NA) protein.

### Claim 2 (depends on 1)

The antibody or antibody fragment of claim 1, wherein the heavy chain variable region and the light chain variable region comprise first and second polypeptides.

### Claim 3 (depends on 2)

The binding agent of claim 2, wherein the antibody or antibody fragment is a monoclonal antibody.

### Claim 4 (depends on 2)

The antibody or antibody fragment of claim 2, wherein the binding agent is an antibody fragment.

### Claim 5 (depends on 1)

The antibody or antibody fragment of claim 1, wherein the heavy chain variable region and the light chain variable region comprise a single polypeptide chain.

### Claim 6 (depends on 1)

A polynucleotide or polynucleotides encoding an antibody or antibody fragment of claim 1.

### Claim 7 (depends on 1)

A pharmaceutical preparation comprising an antibody or antibody fragment of claim 1.

### Claim 8 (depends on 7)

A method comprising administering a therapeutic dose of the pharmaceutical preparation of claim 7 to a subject.

### Claim 9 (depends on 8)

The method of claim 8, wherein said binding agent is co-administered with one or more additional therapeutic agents.

### Claim 10 (depends on 1)

The antibody or antibody fragment of claim 1, comprising a heavy chain variable region of SEQ ID NO: 18 and a light chain variable region of SEQ ID NO: 26.